The European Medicines Agency's (EMEA) decision back in February on recombinant human antithrombin-α, an anticoagulant developed by GTC Biotherapeutics, was eagerly awaited because the product ...
Atryn, a recombinant antithrombin therapy, plays a vital role in preventing blood clots, reducing severe complications, and improving long-term health outcomes for patients with chronic illnesses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback